Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Protalix Biotherapeutics Inc (NYSE MKT LLC:PLX)

Delayed Data
As of Oct 21
 +0.0075 / +1.52%
Today’s Change
Today|||52-Week Range
Health Services
Services to the Health Industry

Company Description

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. Its drug candidates also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. The company was founded on November 30, 1995 and is headquartered in Carmiel, Israel.

Contact Information

Protalix Biotherapeutics, Inc.
2 Snunit Street
Carmiel Haifa 20100
P:(724) 902-8100
Investor Relations:



Mutual fund holders5.25%
Individual stakeholders29.67%
Other institutional26.58%

Top Executives

Moshe ManorPresident, Chief Executive Officer & Director
Tzvi PalashChief Operating Officer
Yossi MaimonCFO, Secretary, Treasurer & Vice President
Yoseph ShaaltielExecutive Vice President-Research & Development
Raul ChertkoffVice President-Medical Affairs